RPRX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
674.1M
+6.9%
630.6M
+1.4%
622.0M
+2.1%
609.3M
+5.3%
578.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
674.1M
+6.9%
630.6M
+1.4%
622.0M
+2.1%
609.3M
+5.3%
578.7M
Operating Expenses
541.0M
+701.1%
67.5M
-71.1%
233.6M
+28.3%
182.1M
-50.6%
368.9M
R&D
97.9M
+145.9%
39.8M
-21.2%
50.5M
+0.0%
50.5M
-83.2%
300.5M
SG&A
161.9M
+1.5%
159.5M
-2.9%
164.3M
+38.4%
118.7M
-34.0%
179.8M
Operating Income
133.1M
-76.4%
563.0M
+45.0%
388.4M
-9.1%
427.2M
+103.6%
209.8M
EBITDA
133.1M
-69.4%
435.0M
-38.5%
707.3M
+61.0%
439.3M
+109.4%
209.8M
Net Income
81.5M
-82.6%
468.3M
+31.6%
355.9M
-19.9%
444.2M
+379.5%
92.6M
EPS (Basic)
$0.04
-94.0%
$0.67
+34.0%
$0.50
-25.4%
$0.67
+737.5%
$0.08
EPS (Diluted)
$0.04
-94.0%
$0.67
+76.3%
$0.38
-43.3%
$0.67
+857.1%
$0.07
Shares (Diluted)
556.9M
+0.0%
556.8M
-0.2%
557.8M
-0.3%
559.6M
-0.5%
562.3M
Royalty Pharma (RPRX) โ€” Financials